{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:35:16Z","timestamp":1793036116777,"version":"4.5.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Peripheral T-cell lymphoma (PTCL) is characterized by its significant variability and complexity as malignancy. Treatment outcome is poor with conventional chemotherapy. We sought to exploring the effectiveness and safety profile of chidamide monotherapy as maintenance regimen after chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>69 patients for PTCL were included in the study and chidamide was administered as maintenance therapy at a dosage of 15\u201330 mg twice weekly (biw). The Kaplan-Meier survival analysis was employed to evaluate overall survival (OS) and progression-free survival (PFS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The average age of participants was 61 years (17-93). The most prevalent pathologic subtype identified was angioimmunoblastic T-cell lymphoma (AITL, 55.1%), and 43.5% (30\/69) of patients were classified as intermediate or high-risk cases. Of the patients, 56.5% (n=39) underwent chidamide maintenance therapy after attaining complete response (CR). Over a median follow-up duration of 43.4 months (21.7-98.4), 47.8% of patients attained CR. The median overall survival (mOS) was not achieved, while the median progression-free survival (mPFS) stood at 54.8 months (95%CI, 21.68-72.78). 20% (6\/30) of PR patients exhibited CR after chidamide. Individuals who attained CR at baseline demonstrated superior PFS compared to those in PR group. Baseline effectiveness was recognized as an independent prognostic indicator for PFS. Neutropenia was the most common hematologic TRAE, with a 20.3% rate of grade 3\/4 events. Dosage modifications were required for 17 patients owing to adverse events, with no fatalities attributed to the treatment reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In patients with PTCL, chidamide as a single-agent maintenance treatment demonstrates effectiveness and favorable tolerability, while the remission status prior to initiating maintenance therapy is a key factor influencing treatment outcomes. Notably, the depth of response after induction therapy alone cannot determine the long-term efficacy in PTCL. Maintenance therapy can not only bring more significant benefits to CR patients but also improve the prognosis of PR patients and reduce the risk of recurrence and progression, highlighting the core value of the \u201cinduction-maintenance\u201d sequential model. Nevertheless, this study is exploratory, and further verification through prospective studies is still required.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1596270","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T04:13:48Z","timestamp":1756786428000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness and safety profile of chidamide as maintenance therapy for peripheral T-cell lymphoma: a multicenter real-world study"],"prefix":"10.3389","volume":"15","author":[{"given":"Wenjing","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changrong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-020-00962-x","article-title":"Advances in the treatment of newly diagnosed peripheral T-cell lymphoma","volume":"48","author":"Zhao","year":"2021","journal-title":"Chin J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-020-00889-z","article-title":"Biomarker-driven management strategies for peripheral T cell lymphoma","volume":"13","author":"Mulvey","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.932914","article-title":"Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment","volume":"13","author":"Sun","year":"2022","journal-title":"Front Pharmacol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20111685","article-title":"CS055 (Chidamide\/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells","author":"Gong","year":"2012","journal-title":"Biochem J"},{"key":"B5","article-title":"Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2\/STAT3 signaling","volume":"8","author":"Zhao","year":"2016","journal-title":"Am J Transl Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3088","article-title":"Chidamide: targeting epigenetic regulation in the treatment of hematological Malignancy","volume":"41","author":"Cao","year":"2023","journal-title":"Hematological Oncology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.875469","article-title":"Chidamide maintenance therapy following induction therapy in patients with peripheral T-cell lymphoma who are ineligible for autologous stem cell transplantation: case series from China","volume":"12","author":"Guo","year":"2022","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"JCO"},{"key":"B10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/oxfordjournals.annonc.a057673","article-title":"Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen","volume":"1","author":"Coiffier","year":"1990","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13148-020-00962-x","article-title":"Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma","volume":"12","author":"Zhang","year":"2020","journal-title":"Clin Epigenet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"a019521","DOI":"10.1101\/cshperspect.a019521","article-title":"Histone modifications and cancer","volume":"8","author":"Audia","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1358\/dot.2017.53.3.2595452","article-title":"Chidamide tablets: HDAC inhibition to treat lymphoma","volume":"53","author":"Xu","year":"2017","journal-title":"Drugs Today"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16227","article-title":"Single-cell landscape reveals the immune heterogeneity of bone marrow involvement in peripheral T-cell lymphoma","volume":"115","author":"Liu","year":"2024","journal-title":"Cancer Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.682436","article-title":"Novel mechanism of action of histone deacetylase inhibitor chidamide: enhancing the chemotaxis function of circulating PD-1(+) cells from patients with PTCL","volume":"11","author":"Wei","year":"2021","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-023-03135-3","article-title":"Long-time follow-up of patients with untreated peripheral T cell lymphoma following chidamide combined with cyclophosphamide, epirubicin, vindesine, prednisone, and etoposide therapy: A single-center propensity score-matching study","volume":"25","author":"Wei","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05708-w","article-title":"Efficacy of Chidamide Maintenance Therapy versus Autologous Stem Cell Transplantation versus Observation as a Post-Remission Choice in the Survival of Adult Patients with Peripheral T-Cell Lymphoma: Post Hoc Analysis of a Prospective, Multicenter, Phase 2 Study in China","volume":"103","author":"Wang","year":"2024","journal-title":"Ann Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0043","article-title":"Romidepsin for the treatment of peripheral T-cell lymphoma","volume":"20","author":"Iyer","year":"2015","journal-title":"Oncologist"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020244","article-title":"Phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma","volume":"142","author":"Merrill","year":"2023","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008418727472","article-title":"Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. classification","volume":"9","author":"L\u00f3pez-Guillermo","year":"1998","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.835103","article-title":"Comparison of chemotherapy combined with chidamide versus chemotherapy in the frontline treatment for peripheral T-cell lymphoma","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"106705","DOI":"10.1016\/j.leukres.2021.106705","article-title":"Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma","volume":"111","author":"Wang","year":"2021","journal-title":"Leukemia Res"},{"key":"B23","article-title":"Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation","volume":"89","author":"Gkotzamanidou","year":"2013","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1162413","article-title":"Retrospective study of autologous hematopoietic stem cell transplantation for peripheral T-cell lymphoma: pre-transplant patients with partial remission benefit from post-transplant maintenance therapy","volume":"13","author":"Huang","year":"2023","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18885","article-title":"Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II\u2013IV peripheral T-cell lymphoma","volume":"202","author":"Stuver","year":"2023","journal-title":"Br J Haematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1596270\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T04:13:49Z","timestamp":1756786429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1596270\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":26,"alternative-id":["10.3389\/fonc.2025.1596270"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1596270","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"article-number":"1596270"}}